(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 2.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Ginkgo Bioworks Holdings's revenue in 2025 is $237,417,000.On average, 2 Wall Street analysts forecast DNA's revenue for 2025 to be $10,506,998,708, with the lowest DNA revenue forecast at $10,478,259,557, and the highest DNA revenue forecast at $10,535,737,860. On average, 2 Wall Street analysts forecast DNA's revenue for 2026 to be $11,726,861,557, with the lowest DNA revenue forecast at $11,355,184,138, and the highest DNA revenue forecast at $12,098,597,508.
In 2027, DNA is forecast to generate $15,668,866,409 in revenue, with the lowest revenue forecast at $15,668,866,409 and the highest revenue forecast at $15,668,866,409.